XW

XWELL, Inc.

XWELHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$29.2M
-13.8% YoY
Net Income
-$17.0M
-0.8% YoY
EBITDA
-$14.2M
-1.3% YoY
Free Cash Flow
-$5.8M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 13 RSI OversoldRSI 28.6, below 30, stock may be oversold
Jul 11 RSI OversoldRSI 28.6, below 30, stock may be oversold
About XWELL, Inc.

XWELL, Inc. engages in the provision of health and wellness services to travelers in the United States and internationally. With a market capitalization of $9.0M, it sits in micro-cap territory. It operates in three segments: XpresSpa, XpresTest, and Naples Wax Center.

Where XWEL stands vs its 150-day and 200-day moving averages

As of the July 13, 2026 close, XWEL finished 3.06% below its 150-day moving average ($0.98) and 1.04% below its 200-day moving average ($0.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is XWEL overbought or oversold?

At the July 13, 2026 close, XWEL's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$9.0M
Fwd P/E-0.41
EPS$-5.49
Beta1.03
52W Change-16.4%
ROE-333.7%
Analysis

With $16.8M in cash and $8.3M in debt, XWEL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$5.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -333.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $55.9M (2022) to $29.2M (2025), a 48% decline worth watching.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XWEL.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
XWEL: XWELL, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance